Frédéric Desdouits graduated from the École Polytechnique (class of 1987), obtained a PhD in Neurosciences from the University of Paris VI, before going on to do postdoctoral research at the Rockefeller University in New York. He is a CEFA (Certified European Financial Analyst) and Certified in Global Management from INSEAD.
After conducting different research activities in the pharmaceuticals industry, he managed the European Pharma and Biotech team at Exane BNP Paribas (1997-2004). He then co-founded and served as managing partner at Bionest Partners (2004-2011), a strategic and financial consulting firm specialized in healthcare and biotechnology. From 2011 to 2017, he worked at the Pierre Fabre group where he set up business development activities and was given responsibility for pharmaceutical activities for North America. From 2017 to 2020, he was head of pharmaceutical activities at Seqens, a global leader in the manufacturing of specialty ingredients, serving as CEO of its publicly-listed subsidiary, PCAS.
Since 2020, he has been CEO of Treefrog Therapeutics, a company which is developing cellular therapies based on a breakthrough technology for cell culture. He is also a Member of the Board of Directors of France Biotech.